P/E ratio for Ligand Pharmaceuticals (LGND)
P/E ratio as of March 2025 (TTM): 69.7
According to Ligand Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 69.7293. At the end of 2022 the company had a P/E ratio of -33.7.
P/E ratio history for Ligand Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -33.7 | -221.14% |
| 2021 | 27.8 | -106.28% |
| 2020 | -443 | -20949.58% |
| 2019 | 2.13 | -83.05% |
| 2018 | 12.5 | -91.19% |
| 2017 | 142 | -122.46% |
| 2016 | -634 | -10933.9% |
| 2015 | 5.85 | -89.6% |
| 2014 | 56.3 | -3.98% |
| 2013 | 58.6 | -100% |
| 2012 | > 1000 | 1.2338542617679E+19% |
| 2011 | 15.1 | -241.22% |
| 2010 | -10.7 | -89.43% |
| 2009 | -101 | 6002.71% |
| 2008 | -1.66 | -255.32% |
| 2007 | 1.07 | -106.41% |
| 2006 | -16.7 | 14.97% |
| 2005 | -14.5 | 21.73% |
| 2004 | -11.9 | 76.66% |
| 2003 | -6.74 | 50.86% |
| 2002 | -4.47 | -70.8% |
| 2001 | -15.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | 22.1 | -68.30% | 🇺🇸 USA |
 | -2.86 | -104.10% | 🇺🇸 USA |
 | 11.3 | -83.87% | 🇬🇧 UK |
 | 51.5 | -26.12% | 🇺🇸 USA |
 | 14.0 | -79.86% | 🇺🇸 USA |
 | 155 | 122.29% | 🇺🇸 USA |
 | 15.3 | -78.06% | 🇺🇸 USA |
 | 6.47 | -90.72% | 🇺🇸 USA |
 | 11.6 | -83.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.